About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research conducted in our group is geared toward elucidating the cause and molecular mechanisms of neurodegeneration in Parkinson's disease (PD), a disabling, currently incurable common neurodegenerative disorder. To this end, we perform clinical and pre-clinical translational research in both PD patients and in human-relevant experimental in vitro and in vivo PD-related models.
Elucidating the molecular mechanisms underlying neurodegeneration in PD should allow to:
IP: Miquel Vila Bover Collaborators: Camille Guillard Sirieix Funding agency: Michael J. Fox Foundation Funding: 163538.22 Reference: SEX_NEUROMELANINE_MJFF2020 Duration: 01/02/2021 - 31/12/2024
IP: Miquel Vila Bover Collaborators: Alba Nicolau Vera, Thais Cuadros Arasa, Marta González Sepúlveda Funding agency: Instituto de Salud Carlos III Funding: 249984.79 Reference: AC20/00121 Duration: 01/01/2021 - 31/12/2024
IP: Miquel Vila Bover Collaborators: Thais Cuadros Arasa, Helena Xicoy Cortada, Marta González Sepúlveda, Annabelle Parent Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 332750 Reference: PID2020-116339RB-I00 Duration: 01/09/2021 - 31/08/2024
IP: Ariadna Laguna Tuset Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Marina Lorente Picón, Helena Xicoy Cortada, Daniela Samaniego Toro, Sara Belmonte Calderon Funding agency: Instituto de Salud Carlos III Funding: 171820 Reference: PI21/01603 Duration: 01/01/2022 - 31/12/2024
PMID: 37075138 Journal: PERFUSION-UK Year: 2023 Reference: Perfusion. 2023 Apr 19:2676591231170480. doi: 10.1177/02676591231170480. Impact factor: Publication type: Paper in international publication Authors: Argudo, Eduard; Barrabes, Jose A; Bonilla, Camilo; Chiscano, Luis; De la Iglesia, Ana; Diaz, Maria Angeles; Ferreira-Gonzalez, Ignacio; Ferrer, Ricard; Font, Marta; Gabaldon, Alejandra et al. DOI: 10.1177/02676591231170480
PMID: 37844866 Journal: NEUROPHARMACOLOGY Year: 2023 Reference: Neuropharmacology. 2023 Oct 14:109759. doi: 10.1016/j.neuropharm.2023.109759. Impact factor: Publication type: Paper in international publication Authors: Benlloch, Luis E; Carcel, Paula; Cedena Romero, Maria Teresa; Crucitti, Davide; De Miguel Sanchez, Carlos; Del Orbe Barreto, Rafael Andres; Diaz Varela, Nicolas A; Diaz-Beya, Marina; Diez-Campelo, Maria; Fernandez-Gonzalez, Pol et al. DOI: 10.1016/j.neuropharm.2023.109759
PMID: 37846799 Journal: CANCER Year: 2023 Reference: Cancer. 2023 Oct 17. doi: 10.1002/cncr.35061. Impact factor: Publication type: Paper in international publication Authors: Bisogno, Gianni; Bouhamama, Amine; Brennan, Bernadette; Brisse, Herve J; Cardoen, Liesbeth; Coma, Ana; Coppadoro, Beatrice; Di Paolo, Pier Luigi; Fayard, Cindy; Fernandez-Gonzalez, Pol et al. DOI: 10.1002/cncr.35061
PMID: 37922009 Journal: INTENSIVE CARE MEDICINE Year: 2023 Reference: Intensive Care Med. 2023 Nov 3. doi: 10.1007/s00134-023-07251-0. Impact factor: Publication type: Editorail in international publication Authors: Ambale-Venkatesh, Bharath; Belohlavek, Jan; Bluemke, David A; Fujii, Tomoki; Gomes, Antoinette S; Hundley, W Gregory; Jung, Christian; Lima, Joao A C; Noda, Chikara; Redhueil, Alban et al. DOI: 10.1007/s00134-023-07251-0
Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.
This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.
Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.
Vall d'Hebron Iniciativa per al Parkinson (VHIP) is a research project aimed at the development of biochemical markers for the early detection of Parkinson's disease. This study is carried out in people at high risk of having this disease, because they carry genetic mutations that predispose to the development of Parkinson's or because they present non-motor symptoms that manifest themselves years before motor symptoms.
